Low-dose clindamycin viable for non-S. aureus prosthetic joint infection

This retrospective cohort offers real-world outcome data for clindamycin 300 mg three times daily as a second-line oral backbone in prosthetic joint infection, including in combination with rifampicin despite a documented pharmacokinetic interaction.

📅 Journal publication: Sep 12, 2026 · Last updated: Sep 14, 2026

clindamycinrifampicinlincosamidesprosthetic joint infectionStaphylococcus aureusCutibacterium acnescoagulase-negative staphylococcistreptococciDAIRretrospective cohortantimicrobial stewardshipIV-to-oraldrug interaction Infectious Disease / Antimicrobials

Background Information

Clindamycin is effective for prosthetic joint infections, though less so for Staphylococcus aureus.

Prosthetic joint infections (PJIs) are challenging to treat due to the risk of recurrence and antibiotic resistance. Evaluating the effectiveness of clindamycin offers insights for alternative therapies. Clindamycin achieved an 82% overall success rate over two years. Success was highest in two-stage exchange (94%), with increased side effects when combined with rifampicin (39% vs 10%). The study suggests clindamycin as a viable option when first-line treatments are unsuitable, but it may be less effective against Staphylococcus aureus. Retrospective nature limits generalizability. Clindamycin shows promise for PJI treatment but may be less effective against Staphylococcus aureus.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Ericsson J, Gustafsson T, Sköldenberg O, Hedenstierna M, Rysinska A, Ursing J

Citation: Ericsson J, Gustafsson T, Sköldenberg O, et al. Effectiveness and tolerability of low dose clindamycin for treatment of prosthetic joint infections, a retrospective cohort study. BMC infectious diseases. 2026;26(1). doi:10.1186/s12879-026-14378-0

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Founding member rate

$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.